Status:
TERMINATED
A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to investigate the effectiveness of Atezolizumab with a primary focus on the overall survival (OS) rate at 2 years and secondary focuses on quality of life (QoL) and the...
Eligibility Criteria
Inclusion
- Metastatic UC (Urothelial Carcinoma) including cancers of the renal pelvis, ureters, urinary bladder, and urethra
- Will be receiving atezolizumab for the treatment of inoperable locally-advanced or metastatic UC, per the decision of the treating physician
- Have adequate hematologic and end-organ functions
- Have had no prior palliative chemotherapy for inoperable locally-advanced or metastatic UC and are clinically ineligible ("unfit") for cisplatin-based chemotherapy
Exclusion
- Have received prior immune checkpoint therapy
- Are pregnant or breastfeeding
- Are included in any other trial
Key Trial Info
Start Date :
December 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 28 2019
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT03399643
Start Date
December 28 2017
End Date
January 28 2019
Last Update
April 19 2019
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Praxis Dr.med. Wolfgang Hölzer
Berlin, Germany, 13055
2
Urologie Schlosscarree
Braunschweig, Germany, 38100
3
Urologische Praxis Dr. Krieger
Chemnitz, Germany, 09127
4
Zeisigwaldkliniken Bethanien
Chemnitz, Germany, 09130